Eli Lilly partnered with Express Scripts to improve adherence for diabetes patients with high-deductible health plans.
The pull-back of insurance providers has left state-run health exchanges and the Obama administration facing a difficult communications challenge.
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
Express Scripts and CVS Health revealed their formularies with Pfizer's Xeljanz making the jump from excluded to preferred for Express Scripts.
States and insurers are lifting restrictions on HCV drugs; Teva's request to join PhRMA raises eyebrows; Merck partners with GPO
UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
The drugmaker instead suggested using an economic model it developed.
OptumRx partners with Walgreens Boots Alliance; Turing's former lawyer said Daraprim price hike was unjustified; the White House names moonshot leader
Novo's Tresiba gets non-preferred status; Valeant's head of dermatology and gastrointestinal products resigns; Trump plans to allow importation of drugs from abroad
The pharmaceutical company reported a 2% revenue increase in 2015, and diabetes medication is a key contributor.
In many cases, the drug required physicians to request prior authorization.
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
- Five things for pharma marketers to know: Friday, February 24, 2017
- MAHF honors Abbate and Lazur, Future Famers
- Five things for pharma marketers to know: Thursday, February 23, 2017
- Almost one-third of programmatic ads violate IAB guidelines, study finds
- Why Pharma Refuses to See Value in 'Influence'